OTLK (STOCKS)
Outlook Therapeutics, Inc. Common Stock
$0.472000
+0.051100 (+12.14%)
Prev close: $0.420900
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Robert Charles Jahr
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $33.46M
- Employees
- 23
- P/E (TTM)
- -0.43
- P/B (TTM)
- -0.55
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q4)
|
$-0.19 | $-0.26 | +0.0684 | +26.47% |
|
Jun 2025 (Q3)
|
$-0.55 | $-0.40 | -0.1488 | -37.09% |
|
Mar 2025 (Q2)
|
$-0.40 | $-0.61 | +0.2100 | +34.43% |
|
Dec 2024 (Q1)
|
$0.72 | $-0.79 | +1.5105 | +191.08% |
Financial Statements
| Revenues | $1.41M |
| Benefits Costs and Expenses | $65.39M |
| Cost Of Revenue | $1.36M |
| Costs And Expenses | $65.39M |
| Gross Profit | $57.21K |
| Operating Expenses | $67.12M |
| Selling, General, and Administrative Expenses | $39.94M |
| Depreciation and Amortization | $117.05K |
| Research and Development | $27.18M |
| Operating Income/Loss | -$67.06M |
| Income/Loss Before Equity Method Investments | -$63.84M |
| Income/Loss From Continuing Operations After Tax | -$62.42M |
| Income/Loss From Continuing Operations Before Tax | -$63.98M |
| Income/Loss From Equity Method Investments | -$141.01K |
| Income Tax Expense/Benefit | -$1.55M |
| Interest Income/Expense After Provision For Losses | -$283.13K |
| Interest Income/Expense Operating, Net | -$283.13K |
| Net Income/Loss | -$62.42M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$62.42M |
| Net Income/Loss Available To Common Stockholders, Basic | -$62.42M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$1.79 |
| Diluted Earnings Per Share | -$1.79 |
| Basic Average Shares | 34,796,120 |
| Diluted Average Shares | 34,796,120 |
| Assets | $18.58M |
| Current Assets | $17.39M |
| Inventory | $3.34M |
| Other Current Assets | $14.05M |
| Noncurrent Assets | $1.20M |
| Liabilities | $50.77M |
| Current Liabilities | $45.81M |
| Accounts Payable | $10.19M |
| Wages | $1.44M |
| Other Current Liabilities | $34.19M |
| Noncurrent Liabilities | $4.96M |
| Equity | -$32.19M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$32.19M |
| Liabilities And Equity | $18.58M |
| Net Cash Flow From Operating Activities | -$51.83M |
| Net Cash Flow From Operating Activities, Continuing | -$51.83M |
| Net Cash Flow From Investing Activities | $6.84M |
| Net Cash Flow From Investing Activities, Continuing | $6.84M |
| Net Cash Flow From Financing Activities | $44.98M |
| Net Cash Flow From Financing Activities, Continuing | $44.98M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$62.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$62.42M |
| Other Comprehensive Income/Loss | $0.00 |